New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROIAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.PALO ALTO, Calif. — Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience data from Medable.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe Tufts CSDD analysis specifically assessed the impact of Medable’s Clinical Monitoring Agent across three top-line metrics:Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againExpected net present value: The agent showed eNPV gains of approximately $7.5 million (phase 2 trial), $11.3 million (combined phase 2 and phase 3) development, and $21 million (phase 3 trial).Overall return on investment: The study found an estimated ROI of 64x for phase 2 and 82x for phase 3 clinical trials.Direct operating cost savings: Tufts CSDD estimated direct operating cost reductions in on-site monitoring per clinical trial of approximately $4.4 million per phase 2 and $5.6 million per phase 3 study.“To our knowledge, this is the first time that eNPV modeling based on actual use and benchmark data has been applied to quantify the net financial impact of an agentic AI solution deployed to support a drug development program,” said Ken Getz, Tufts CSDD Executive Director. “The financial value created by the investment and deployment of the monitoring agent was driven by operational efficiencies such as the reduction in the number of on-site visits and reduced travel costs as well as accelerated enrollment and database lock timelines.”Additional analysis identified and valued administrative off-site monitoring task efficiencies of approximately $600,000 (phase 2) and $1.7 million (phase 3). These savings reflect clinical research associate time that could be reallocated to other studies and were not included in the eNPV calculations.The analysis also found that agentic AI can accelerate clinical development by approximately 18 weeks. By shortening activities on the critical path of development, agents help sponsors complete studies sooner, advancing regulatory submission and potential commercialization while increasing the expected financial value. Key contributors include:– Faster patient enrollment, reducing enrollment timelines by approximately 109–119 days – Earlier database lock, shortening closeout activities by about two weeks – Earlier realization of future revenue and lower development costs“The potential impact is magnified when applied across a large oncology portfolio,” said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. “For a sponsor with 20 active indications, deploying a clinical monitoring agent across phase 2 and 3 studies could generate as much as $226 million in incremental portfolio eNPV. For a sponsor with 50 active indications, that figure could jump to as much as $565 million. Bottom line? We now have evidence demonstrating sizable value creation of agents in clinical research, helping break longstanding barriers.”In addition to these high-level findings, Tufts and Medable will publish a detailed, peer-reviewed paper later this year. Sign up to be the first to receive the final published paper here.Tufts CSDD Analysis MethodologyMedable partnered with Tufts CSDD, the leading independent research group on clinical development economics, to empirically answer the question: To what extent can clinical monitoring agents improve trial performance, and do those translate into measurable economic value for drug developers? Medable provided operational data – including time savings and agent cost – from its Clinical Monitoring Agent modeled in an oncology development program. Tufts CSDD applied the expected Net Present Value (eNPV) framework, a widely accepted method for quantifying the financial impact of innovation investments, to assess the value created by the AI agent.About Tufts Center for the Study of Drug Development (CSDD)The Tufts Center for the Study of Drug Development is an independent academic research center that conducts objective analyses of the scientific, economic, and policy factors affecting pharmaceutical innovation and clinical development.Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.comView source version on businesswire.com: Lisa Barbadora, Barbadora INK for MedableThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.